Literature DB >> 7994935

Diuretics potentiate angiotensin converting enzyme inhibitor-induced acute renal failure.

A K Mandal1, R J Markert, M G Saklayen, R A Mankus, K Yokokawa.   

Abstract

Previous studies suggest that angiotensin converting enzyme (ACE) inhibitors cause reversible acute renal failure (ARF) in patients with hypertension, congestive heart failure (CHF), and renal disease. These patients often receive diuretics concomitantly with ACE inhibitors. The purpose of this study was to examine whether ACE inhibitors alone produce ARF or whether they do so when used in combination with diuretics. The medical records of patients taking ACE inhibitors without or with diuretics were reviewed. Complete data from 74 patients were obtained and the data were analyzed. These 74 patients had a diagnosis of hypertension, CHF or diabetes mellitus. BUN and serum creatinine values before, during, and after discontinuation of ACE inhibitor therapy for a mean period of 8.7 months were collected. Seventy-four patients were divided into two groups: Group A (n = 41) patients who received ACE inhibitors alone; Group B (n = 33) patients who received a combination of an ACE inhibitor and a diuretic. ARF developed in 1 of 41 (2.4%) Group A patients compared to 11 of 33 (33%) Group B patients. This group difference was highly significant (P < .001). In Group A, mean serum creatinine before (1.24 +/- .34 mg/dl) was identical to that 1.23 +/- .33 mg/dl) after 8.7 months of ACE inhibitor therapy, whereas in Group B, post-mean serum creatinine (3.11 +/- 2.27 mg/dl) was significantly (P < .01) higher than pre-mean serum creatinine (1.65 +/- .85 mg/dl). CHF patients had a higher rate of ARF than patients with other diagnoses. Urinary electrolytes showed that 4 of 6 Group B patients had chloride concentration less than 20 mEq/l.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7994935

Source DB:  PubMed          Journal:  Clin Nephrol        ISSN: 0301-0430            Impact factor:   0.975


  9 in total

1.  Reversible impairment of renal function associated with enalapril in a diabetic patient.

Authors:  M M Albareda; R Corcoy
Journal:  CMAJ       Date:  1998-11-17       Impact factor: 8.262

Review 2.  Lisinopril. A review of its pharmacology and use in the management of the complications of diabetes mellitus.

Authors:  K L Goa; M Haria; M I Wilde
Journal:  Drugs       Date:  1997-06       Impact factor: 9.546

3.  Arterial hypertension treated with angiotensin converting enzyme inhibitors and glucocorticoids are independent risk factors associated with decreased glomerular filtration rate in systemic sclerosis.

Authors:  Predrag Ostojic; Natasa Stojanovski
Journal:  Rheumatol Int       Date:  2016-12-22       Impact factor: 2.631

Review 4.  Management of acute renal failure in the elderly. Treatment options.

Authors:  A K Mandal; M Baig; Z Koutoubi
Journal:  Drugs Aging       Date:  1996-10       Impact factor: 3.923

Review 5.  Lisinopril. A review of its pharmacology and clinical efficacy in the early management of acute myocardial infarction.

Authors:  K L Goa; J A Balfour; G Zuanetti
Journal:  Drugs       Date:  1996-10       Impact factor: 9.546

Review 6.  Lisinopril. A review of its pharmacology and clinical efficacy in elderly patients.

Authors:  H D Langtry; A Markham
Journal:  Drugs Aging       Date:  1997-02       Impact factor: 3.923

7.  Fractional excretion of sodium predicts worsening renal function in acute decompensated heart failure.

Authors:  Fadi T Alattar; Nasha't Imran; Vincent A Debari; Kozhaya N Mallah; Fayez E Shamoon
Journal:  Exp Clin Cardiol       Date:  2010

8.  Angiotensin-converting enzyme inhibitors predict acute kidney injury during chemoradiation for head and neck cancer.

Authors:  Michael T Spiotto; Hongyuan Cao; Loren Mell; F Gary Toback
Journal:  Anticancer Drugs       Date:  2015-03       Impact factor: 2.248

9.  Impact of acute kidney injury in patients prescribed angiotensin-converting enzyme inhibitors over the first two years of life.

Authors:  Daishi Hirano; Saori Miwa; Daisuke Kakegawa; Chisato Umeda; Yoichi Takemasa; Ai Tokunaga; Kawakami Yuhei; Akira Ito
Journal:  Pediatr Nephrol       Date:  2021-01-19       Impact factor: 3.714

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.